Physician profile
Brian M Scott
NPI 1851345755
$2,668.84
in general payments reported to CMS, 2019-2025
22 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.92 · 2020: $12.14 · 2021: $263 · 2022: $316 · 2023: $610 · 2024: $787 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.61 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $408.67 | 2020-2025 | |
| Novo Nordisk INC | $253.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $241.58 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $162.55 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $158.80 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $157.94 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $129.82 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $62.35 | 2025 | Korlym |
| Amarin Pharma, INC. | $57.93 | 2019-2022 | |
| Exact Sciences Corporation | $54.59 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $37.70 | 2022 | |
| Ethicon INC. | $36.63 | 2024 | Monarch Platform |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.26 | 2023 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.63 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $24.30 | 2025 | Auvelity |
| Shield Therapeutics INC | $23.61 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $22.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.41 | 2022 | |
| Endogastric Solutions, INC | $20.07 | 2023 | Esophyx |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.